All In Biotech

Drug Trial Radar · NCT06018428

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Sep 12, 2023

Primary completion

Jun 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Q32 Bio Inc.Industry
Sponsor type
Industry
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.

Conditions

  • Alopecia Areata

Interventions

  • bempikibart (ADX-914)Drug

    Subcutaneous administration of bempikibart (ADX-914)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Mean relative percent change in SALT scoreTime frame: 24 Weeks
  2. Part B: Mean percent change from baseline in SALT scoreTime frame: 36 weeks

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • Scottsdale, Arizona

    Scottsdale, Arizona

  • Fayetteville, Arkansas

    Fayetteville, Arkansas

  • Hot Springs, Arkansas

    Hot Springs, Arkansas

  • Encinitas, California

    Encinitas, California

  • Fountain Valley, California

    Fountain Valley, California

  • Lomita, California

    Lomita, California

  • New Haven, Connecticut

    New Haven, Connecticut

  • Miami, Florida

    Miami, Florida

  • Tampa, Florida

    Tampa, Florida

  • Clarksville, Indiana

    Clarksville, Indiana

  • Bowling Green, Kentucky

    Bowling Green, Kentucky

  • Burlington, Massachusetts

    Burlington, Massachusetts

  • Troy, Michigan

    Troy, Michigan

  • Warren, Michigan

    Warren, Michigan

  • New York, New York

    New York, New York

  • New York, New York

    New York, New York

  • Wilmington, North Carolina

    Wilmington, North Carolina

  • Bexley, Ohio

    Bexley, Ohio

  • Clinical Trials

    Canton, Ohio

  • Mason, Ohio

    Mason, Ohio

  • Mayfield Heights, Ohio

    Mayfield Heights, Ohio

  • Portland, Oregon

    Portland, Oregon

  • Austin, Texas

    Austin, Texas

  • Frisco, Texas

    Frisco, Texas

  • Houston, Texas

    Houston, Texas

  • San Antonio, Texas

    San Antonio, Texas

  • Jordan, Utah

    Jordan, Utah

  • Spokane, Washington

    Spokane, Washington

  • Clinical Trials

    Calgary, Alberta, Canada

  • Clinical Trials

    Winnipeg, Manitoba, Canada

  • Clinical Trials

    Oakville, Ontario, Canada

  • Clinical Trials

    Peterborough, Ontario, Canada

  • Clinical Trials

    Waterloo, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.